Avidity Partners Management’s Karyopharm Therapeutics KPTI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.08M Sell
884,900
-39,587
-4% -$162K 0.22% 15
2026
Q2
$9.03M Buy
924,487
+460,746
+99% +$4M 1.45% 13
2026
Q1
$2.58M Buy
463,741
+329,175
+245% +$2.51M 0.52% 21
2025
Q4
$990K Hold
134,566
– – 0.29% 38
2025
Q3
$880K Hold
134,566
– – 0.2% 42
2025
Q2
$580K Hold
134,566
– – 0.12% 53
2025
Q1
$503K Sell
134,566
-1
-0% -$9 0.1% 64
2024
Q4
$1.37M Hold
134,567
– – 0.13% 61
2024
Q3
$1.68M Hold
134,567
– – 0.09% 78
2024
Q2
$1.75M Sell
134,567
-418,671
-76% -$6.93M 0.07% 81
2024
Q1
$12.5M Hold
553,238
– – 0.4% 65
2023
Q4
$7.18M Hold
553,238
– – 0.26% 64
2023
Q3
$11.1M Sell
553,238
-4,769
-0.9% -$107K 0.45% 64
2023
Q2
$15M Sell
558,007
-84,254
-13% -$3.63M 0.52% 64
2023
Q1
$37.5M Hold
642,261
– – 1.24% 32
2022
Q4
$32.8M Buy
+642,261
New +$44.5M 0.71% 41

Other funds holding KPTI

Avidity Partners Management's KPTI Position: Q3 2026 in Review

Avidity Partners Management reduced its Karyopharm Therapeutics (KPTI) stake by 4.3% in Q3 2026, selling an estimated $162K and leaving 884,900 shares worth $1.08M. The position accounts for 0.22% of the portfolio, ranked #15.

Avidity Partners Management first reported a position in KPTI in Q4 2022 and has held it in 16 quarters since. The position peaked at $37.5M in Q1 2023. 92 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.

  • Avidity Partners Management held 884,900 shares of Karyopharm Therapeutics worth $1.08M as of Q3 2026.
  • Avidity Partners Management sold 39,587 Karyopharm Therapeutics shares in Q3 2026, an estimated $162K.
  • Karyopharm Therapeutics made up 0.22% of Avidity Partners Management's portfolio in Q3 2026, its #15 holding.
  • Avidity Partners Management first reported a position in Karyopharm Therapeutics in Q4 2022 and has held it in 16 quarters since.
  • Avidity Partners Management's Karyopharm Therapeutics position peaked at $37.5M in Q1 2023.
  • 92 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.

Based on Avidity Partners Management's 13F filing for Q3 2026, filed 16 Nov 2026.